亚辉龙(688575) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 reached ¥1,369,921,651.93, representing a year-over-year increase of 481.55%[6] - Net profit attributable to shareholders was ¥511,409,206.22, reflecting a significant increase of 1,257.79% compared to the same period last year[6] - Basic earnings per share were ¥1.26, up 1,160.00% from the previous year[6] - Total operating revenue reached approximately $1.37 billion, a significant increase from $235.56 million in the previous period[32] - Net profit for the period was approximately $508.16 million, compared to $36.91 million in the same period last year[34] - Operating profit was approximately $591.95 million, compared to $43.68 million in the previous year[32] - The company reported a total profit of approximately $590.85 million, compared to $43.32 million in the previous year[32] Cash Flow and Assets - The net cash flow from operating activities was ¥558,644,893.43, an increase of 10,664.60% year-over-year[6] - Cash flow from operating activities generated approximately $558.64 million, a substantial increase from $5.19 million in the prior year[38] - The company's current assets reached RMB 2,048,056,874.60, up from RMB 1,178,049,537.13, indicating a growth of about 74% year-over-year[22] - Cash and cash equivalents increased significantly to RMB 1,022,352,244.52 from RMB 478,851,013.46, representing a growth of approximately 113.5%[22] - The ending balance of cash and cash equivalents reached $1.02 billion, up from $177.8 million at the end of the previous period[40] - The net increase in cash and cash equivalents was $541.2 million, contrasting with a decrease of $51.4 million in the previous year[40] Liabilities and Equity - The company's total liabilities rose to RMB 1,082,385,867.13, compared to RMB 623,591,625.04, marking an increase of around 73.5%[28] - The equity attributable to shareholders increased to RMB 2,046,324,098.43 from RMB 1,525,711,800.99, showing a growth of about 34.1%[28] - Short-term borrowings increased to RMB 223,682,280.00 from RMB 150,818,258.16, indicating a rise of about 48.3%[26] - Long-term borrowings also saw an increase, reaching RMB 98,185,423.67 compared to RMB 73,255,122.40, which is an increase of approximately 34.1%[28] Research and Development - R&D expenses totaled ¥57,562,786.50, marking a 93.94% increase, while the ratio of R&D expenses to revenue decreased by 8.40 percentage points to 4.20%[9] - Research and development expenses amounted to approximately $54.80 million, up from $29.68 million year-over-year[32] Inventory and Operating Costs - The company reported a significant increase in inventory, which rose to RMB 561,407,400.94 from RMB 363,805,774.69, reflecting a growth of approximately 54.3%[22] - Total operating costs were approximately $768.64 million, compared to $191.42 million in the previous period[32] Tax and Other Income - Tax expenses for the period were approximately $82.69 million, compared to $6.41 million in the same period last year[32] - Non-recurring gains and losses amounted to ¥1,800,946.14 for the period[11] - Other comprehensive income after tax was reported at approximately -$473,148.78, compared to -$158,790.27 in the previous year[34] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,534[16] Company Strategy and Market - The company attributed the revenue growth primarily to significant overseas sales of COVID-19 antigen test kits[12] - The company has not disclosed any new product developments or market expansion strategies in the provided content[20]